← Eichor
Condition: Solid Tumors Refractory To Standard Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Solid Tumors Refractory To Standard Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Rabin Medical Center · NCT06940349A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Phase 1 · 2 location(s) · LaunXP Biomedical Co., Ltd. · NCT06883539AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Avelos Therapeutics Inc. · NCT06911333SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid T
Phase 1 · 11 location(s) · Qurgen Inc. · NCT06873659Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Phase 2 · 1 location(s) · Sheng Zhang · NCT07309770
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.